Bristol-Myers Squibb Company’s (BMY – Analyst Report) first-quarter 2015 earnings (excluding special items) of 71 cents per share beat the Zacks Consensus Estimate of 50 cents and were up 54% year over year.
Bristol-Myers Squibb Company – Quarterly EPS | FindTheCompany
Net sales (excluding revenues from the diabetes alliance) in the first quarter climbed 10% to approximately $4 billion, driven by strong sales of drugs targeting the oncology market. Strong sales of the company’s rheumatoid arthritis drug, Orencia and anti-clotting drug Eliquis also boosted the top line in the reported quarter.
